Antimicrobial Stewardship and the Microbiology Laboratory: How Bench Decisions Shape Prescribing

A blood culture flags positive at 2 a.m. The patient is septic, and the team starts a broad carbapenem, the safe empirical guess. Two days later, the laboratory reports the organism as an E. coli susceptible to cefazolin. The team narrows the therapy, the patient recovers, and a carbapenem that would have been spent unnecessarily is preserved for the next patient who truly needs it.

Nothing about that de-escalation happened at the bedside alone. It happened because the laboratory identified the organism, tested it correctly, and reported the result in a way that made the narrow choice obvious. That is antimicrobial stewardship, and the microbiologist was in the middle of it. This article is about that role: not stewardship as a hospital committee, but stewardship as it is practiced from the bench.

What antimicrobial stewardship is

Antimicrobial stewardship is the coordinated effort to use antimicrobials appropriately: the right drug, at the right dose, by the right route, for the right duration, so that patients are treated effectively while the emergence of resistance is slowed and existing antimicrobials are preserved.

Antimicrobials are the only class of drugs that lose effectiveness the more they are used, which is what makes their conservation a shared responsibility rather than a private prescribing choice.

Why the laboratory sits at the center of stewardship

A stewardship program can write policies, restrict drugs, and audit prescriptions, but every one of those actions depends on data the laboratory produces. The susceptibility report is the single most powerful stewardship intervention available, because it reaches the prescriber at the exact moment of decision and tells them what will work.

A committee guideline is general advice; a susceptibility report is specific instruction about this patient's organism. The microbiologist therefore does not merely support stewardship from the outside. The laboratory is where the evidence for every stewardship decision is generated.

The laboratory's stewardship levers

There are six concrete ways the microbiology lab shapes prescribing. Each is a working tool, and most already have a dedicated article on this site.

1. The antibiogram: guiding the empirical guess. Before any result is available, clinicians must treat empirically. The antibiogram, the laboratory's cumulative summary of local susceptibility data over a period, is what makes that guess evidence-based rather than habitual. If local E. coli is 30% resistant to ciprofloxacin, the antibiogram tells the whole institution to stop using ciprofloxacin empirically for those infections. This is stewardship at the population level, built entirely from laboratory data, and it is only as good as the AST behind it (see the antimicrobial susceptibility testing hub).

2. Selective (restricted) reporting: steering the choice. The laboratory does not have to report every drug it tests. By releasing only the narrowest effective agents and withholding broad-spectrum ones unless needed, the report itself nudges the prescriber toward the narrow choice. A clinician who never sees "meropenem: susceptible" on the report is far less likely to prescribe it. This is one of the most direct stewardship tools the bench controls, and it is covered in full in the selective reporting article.

3. Cascade reporting: releasing breadth only when earned. A refinement of selective reporting. Broader-spectrum agents are reported only when the isolate is resistant to the narrow-spectrum first choices, so the clinician sees the broad option exactly when it becomes necessary and not before. The report unfolds in tiers that mirror good prescribing.

4. Resistance-mechanism detection as a prescribing decision. When the laboratory confirms an ESBL, an AmpC, or a carbapenemase, it is not filing a fact, it is changing the drug. An ESBL result moves therapy toward a carbapenem. An AmpC result rules out third-generation cephalosporins and points to cefepime or a carbapenem. A carbapenemase result forces a move to last-line agents and triggers infection control. Every mechanism the bench detects is a fork in the prescribing road, which is why the detection spokes in this cluster are stewardship tools, not just diagnostic exercises.

5. Rapid diagnostics: shortening the empirical window. The faster an organism is identified and its susceptibility known, the sooner broad empirical therapy can become narrow targeted therapy. Rapid identification methods and rapid AST compress the window during which a patient is on a best-guess broad-spectrum drug, which is the window stewardship most wants to shorten.

6. Supporting de-escalation and the D-test decision. Once a susceptibility result is available, the laboratory's job is to make de-escalation safe. The D-test, for example, exists precisely so a clinician does not de-escalate to clindamycin against an organism that will develop resistance mid-treatment. The bench does not just permit narrowing; it defines when narrowing is safe.

The prescribing-side complement: AWaRe

The laboratory shapes what is reported; the WHO AWaRe classification shapes how those drugs are valued. AWaRe sorts antibiotics into Access, Watch, and Reserve tiers so that the drugs worth protecting are used most sparingly.

A stewardship-minded laboratory reports with AWaRe in mind, favoring Access agents in what it releases and guarding Reserve agents behind confirmed need. The two systems work together: the AWaRe framework sets the priorities, and laboratory reporting enacts them.

The microbiologist as a member of the stewardship team

Formal stewardship programs are multidisciplinary, typically led by an infectious-disease physician and a clinical pharmacist. The clinical microbiologist is a core member, and brings what no one else on the team can: the diagnostic data, the resistance surveillance, the antibiogram, and the interpretive expertise to say what a result actually means for therapy. This is the role the current MD Microbiology curriculum trains for. Stewardship is not a topic microbiologists learn about. It is a responsibility they carry.

How to Remember

The one-line thesis of the whole article: a susceptibility report is not a record of what the bug is resistant to. It is a prescribing instruction, and every choice the laboratory makes about what to test, what to report, and how to report it is a stewardship decision.

The six levers, grouped so they stick: think of the laboratory acting across the timeline of a single infection. Before results exist, the antibiogram guides the empirical guess and rapid diagnostics shorten the wait. When results are ready, selective and cascade reporting steer the choice, and resistance detection forks the road. After the choice, the lab makes de-escalation safe. Before, during, after: two levers at each stage.

Why antibiotics are different, in one image: every other drug in the pharmacy is a private transaction between one patient and one prescription. An antibiotic is a shared resource, using it today makes it work less well for everyone tomorrow. Stewardship is what turns a private prescribing decision back into a shared responsibility, and the laboratory holds the data that makes that possible.

Key exam facts in one table

Where Students Get Confused

"Stewardship is an administrative program, not a lab activity." The program is administrative; the evidence for every decision it makes is generated in the laboratory. The bench is not outside stewardship, it is the source of the data stewardship runs on.

"The lab reports everything it tests." No. Selective and cascade reporting mean the laboratory deliberately withholds some results to steer prescribing. What is left off the report is a stewardship choice as deliberate as what is put on it.

"Detecting a resistance mechanism is just diagnosis." It is also a prescribing decision. Confirming an ESBL, AmpC, or carbapenemase changes the drug the patient receives, which is stewardship in action.

"De-escalation means giving fewer antibiotics." It means giving the right, narrower antibiotic once the organism is known, not simply giving less. The goal is targeted therapy, not reduced therapy.

"Stewardship is only about saving money." Cost savings are a byproduct. The primary goals are better patient outcomes and preserving antimicrobial effectiveness for the future.

References

1. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-e77. doi:10.1093/cid/ciw118
2. World Health Organization. WHO AWaRe (Access, Watch, Reserve) classification of antibiotics for evaluation and monitoring of use. Geneva: WHO; current edition.
3. Dyar OJ, Huttner B, Schouten J, Pulcini C. What is antimicrobial stewardship? Clin Microbiol Infect. 2017;23(11):793-798. doi:10.1016/j.cmi.2017.08.026
4. Morency-Potvin P, Schwartz DN, Weinstein RA. Antimicrobial Stewardship: How the Microbiology Laboratory Can Right the Ship. Clin Microbiol Rev. 2016;30(1):381-407. doi:10.1128/CMR.00066-16
5. Tille PM. Bailey & Scott's Diagnostic Microbiology. 15th ed. St. Louis: Elsevier; 2022.